- Home
- EU vs PLRX Comparison
EU vs PLRX Comparison
Compare EU & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | PLRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.9M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EU | PLRX |
|---|---|---|
| Price | $2.42 | $1.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | ★ $4.00 | $3.79 |
| AVG Volume (30 Days) | ★ 2.8M | 1.9M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,142,000.00 | N/A |
| Revenue This Year | $17.41 | N/A |
| Revenue Next Year | $95.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $1.10 |
| 52 Week High | $4.19 | $13.71 |
Technical Indicators
Market Signals| Indicator | EU | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 38.96 |
| Support Level | $2.28 | $1.20 |
| Resistance Level | $2.54 | $1.25 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.73 | 22.58 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.